PGY2 Oncology Pharmacy Residency

At Jack & Sheryl Morris Cancer Center

Purpose

The PGY2 oncology residency program builds upon Doctor of Pharmacy (PharmD) education and PGY1 pharmacy residency training to develop pharmacist practitioners with knowledge, skills, and abilities as defined in the educational competency areas, goals, and objectives for advanced practice areas. Residents who successfully complete the PGY2 oncology residency program are prepared for advanced patient care or other specialized positions, and board certification in the advanced practice area, if available.

Program Goals

The Jack & Sheryl Morris Cancer Center in New Brunswick, New Jersey is the state’s first and only freestanding cancer hospital providing advanced inpatient and outpatient cancer care services offered by New Jersey’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, Rutgers Cancer Institute (RCI) and RWJBarnabas Health (RWJBH).

The RWJBH PGY2 Oncology Pharmacy Residency Program at Jack & Sheryl Morris Cancer Center is a 12-month educational and training experience designed to develop expert knowledge, skills, and leadership in the practice of oncology pharmacy. Residents will gain well-rounded experiences and provide direct patient care in a variety of clinical oncology specialties, including inpatient and outpatient adult solid and hematologic malignancies, pediatric oncology, and investigational drug services. Additionally, residents will be involved in various educational, administrative, and research projects and presentations. Upon completion of the residency program, residents will be prepared to practice at the top of their license as a board-certified oncology clinical pharmacist.

Application Deadline: January 4, 2027

Residency Start Date: July 6, 2027

Number of Positions: 1